Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Skin sensitivity as a marker of efficacy for house dust mite allergen immunotherapy
ChiCTR1800019744Phase 4Not yet recruiting
- Sponsor
- Institute of Dermatology, Chinese Academy of Medical Sciences
- Start
- Dec 2018
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of alutard-sq in allergic rhinitis (AR), atopic dermatitis (AD) and asthma (2 arms), sponsored by Institute of Dermatology, Chinese Academy of Medical Sciences. Primary endpoints: Medication use and symptom scores at 3 years, Allergen skin prick test sensitivity at 3 years and 1 more. Planned start Dec 2018; status: not yet recruiting.
02
Drugs
alutard-sq
03
Conditions
allergic rhinitis (AR)atopic dermatitis (AD)asthma
Beyond the preview
Go deeper on ChiCTR1800019744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019744.